Adaptive Biotechnologies (NASDAQ:ADPT) Insider Harlan Robins Sells 8,120 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 8,120 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $19.00, for a total transaction of $154,280.00. Following the transaction, the insider directly owned 1,179,524 shares of the company’s stock, valued at $22,410,956. This represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Adaptive Biotechnologies Price Performance

Shares of ADPT stock opened at $17.30 on Thursday. Adaptive Biotechnologies Corporation has a 1 year low of $6.26 and a 1 year high of $20.76. The company’s fifty day simple moving average is $17.17 and its two-hundred day simple moving average is $15.15. The stock has a market capitalization of $2.64 billion, a price-to-earnings ratio of -32.04 and a beta of 2.18.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.01. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. The firm had revenue of $93.97 million for the quarter, compared to analysts’ expectations of $58.76 million. During the same quarter in the prior year, the firm posted ($0.22) earnings per share. The business’s quarterly revenue was up 102.4% on a year-over-year basis. Equities research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of institutional investors and hedge funds have recently modified their holdings of the company. Ameriprise Financial Inc. lifted its stake in shares of Adaptive Biotechnologies by 84.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after purchasing an additional 2,731,648 shares during the period. Arrowstreet Capital Limited Partnership increased its stake in shares of Adaptive Biotechnologies by 544.0% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock worth $36,523,000 after purchasing an additional 2,062,282 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of Adaptive Biotechnologies by 103.9% during the fourth quarter. Jennison Associates LLC now owns 2,674,668 shares of the company’s stock valued at $43,437,000 after acquiring an additional 1,363,181 shares during the last quarter. Summit Partners Public Asset Management LLC acquired a new position in Adaptive Biotechnologies in the 3rd quarter valued at $14,934,000. Finally, First Trust Advisors LP lifted its stake in shares of Adaptive Biotechnologies by 4,802.2% in the second quarter. First Trust Advisors LP now owns 741,306 shares of the company’s stock worth $8,636,000 after buying an additional 726,184 shares in the last quarter. Institutional investors and hedge funds own 99.17% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on ADPT shares. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 7th. Wall Street Zen lowered shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Piper Sandler increased their target price on Adaptive Biotechnologies from $15.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Finally, Guggenheim raised their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a report on Monday, January 26th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Adaptive Biotechnologies has a consensus rating of “Moderate Buy” and a consensus target price of $17.22.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.